Maraviroc (UK-427857)

Catalog No. A10556

Maraviroc (UK-427857)是CCR5受体拮抗剂类别的抗逆转录病毒药物，用于治疗HIV感染。

Product Citations

Roman V Uzhachenko, .et al. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors, Cell Rep, 2021, Apr 6;35(1):108944 PMID: 33826903
Karampoor S, .et al. Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis, Int Immunopharmacol, 2020, Mar;80:106138 PMID: 32007705
Taisuke Ito, .et al. CCR5 is a novel target for the treatment of experimental alopecia areata, JCIA, 2020, 22 January

Technical details

Catalog Num	A10556
M. Wt	513.7
Formula	C29H41F2N5O
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	376348-65-1
Synonyms	UK-427857, Celsentri
SMILES	CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C

Biological Activity

Maraviroc (UK-427857)是CCR5受体拮抗剂类别的抗逆转录病毒药物，用于治疗HIV感染。

Targets

MIP-1α (Cell-free assay)	RANTES (Cell-free assay)	MIP-1β (Cell-free assay)
3.3 nM	5.2 nM	7.2 nM

Solubility *

In vitro (25°C)	DMSO	91 mg/mL (177.15 mM)
	Water	Insoluble
	Ethanol	91 mg/mL (177.15 mM)
In vivo	2% DMSO+corn oil	9 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	19.47 mL	97.33 mL	194.67 mL
0.5 mM	3.89 mL	19.47 mL	38.93 mL
1 mM	1.95 mL	9.73 mL	19.47 mL
5 mM	0.39 mL	1.95 mL	3.89 mL

*The above data is based on the productmolecular weight 513.7. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.